Drug intelligence / Profile preview

Tivirapine

Development stage: Phase 2
Modality: Small Molecules

Overview

Tivirapine is a small molecule, benzodiazepine non-nucleoside reverse transcriptase inhibitor (NNRTI) that demonstrates activity against human immunodeficiency viruses 1 and 2 (HIV-1 and HIV-2), as well as simian immunodeficiency virus. It functions by inhibiting the replication of these viruses, including both wild-type and drug-resistant HIV-1 isolates. The drug has progressed to a maximum of Phase II clinical trials.

Targets

Human immunodeficiency virus type 1 reverse transcriptaseCYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on Tivirapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tivirapine.

Explore the full profile